2016
LC3/GABARAP family proteins: autophagy-(un)related functions. Schaaf MB, Keulers TG, Vooijs MA, Rouschop KM. FASEB J. 2016 Sep 6. pii: fj.201600698R.
Decision support systems for personalized and participative radiation oncology. Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S.
Adv Drug Deliv Rev. 2016 Jan 14. pii: S0169-409X(16)30008-4. doi: 10.1016/j.addr.2016.01.006. [Epub ahead of print] Review.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Klionsky DJ, Abdelmohsen K et al. Autophagy. 2016 Jan 2;12(1):1-222.
Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Van Gisbergen MW, Cebula M, Zhang J, Ottosson-Wadlund A, Dubois L, Lambin P, Tew KD, Townsend DM, Haenen GF, Drittij-Reijnders MJ, Saneyoshi H, Araki M, Shishido Y, Ito Y, Arnér ES, Abe H, Morgenstern R, Johansson K. Mol Pharm. 2016 Apr 28. [Epub ahead of print]
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis.
van Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Front Oncol. 2016 Mar 29;6:69. doi: 10.3389/fonc.2016.00069. eCollection 2016. Review.
In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. Panth KM, van den Beucken T, Biemans R, Lieuwes NG, Weber M, Losen M, Yaromina A, Dubois LJ, Lambin P. Sci Rep. 2016 Feb 29;6:22198. doi: 10.1038/srep22198.
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LM, van Hoof SJ, Groot AJ, Habets R, Prickaerts J, Chalmers AJ, Eekers DB, Theys J, Short SC, Verhaegen F, Vooijs M.
Oncotarget. 2016 May 10. doi: 10.18632/oncotarget.9275. [Epub ahead of print]
Targeting Notch to overcome radiation resistance. Yahyanejad S, Theys J, Vooijs M. Oncotarget. 2016 Feb 16;7(7):7610-28. doi: 10.18632/oncotarget.6714. Review.
Benefits, limitations and opportunities of NOTCH inhibitors for treatment of Glioma. Sanaz Yahyanejad, Patrick V. Granton, Ann Hoeben, Marc A. Vooijs. Translational Cancer Research. doi: 10.21037/tcr.2016.07.26
Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3. Dahlmans VE, Gits C, Evelo CT, Chan-Seng-Yue M, Wouters BG, Voncken JW. Epigenetics Chromatin. 2016 Oct 26;9:46. eCollection 2016
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative ch... - PubMed - NCBI. Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P. BMC Cancer. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z.See comment in PubMed Commons below
New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. Simon J.A. van Kuijk, Nanda Kumar Parvathaneni , Raymon Niemans, Marike W. van Gisbergen, Fabrizio Cartac, Daniela Vullo, Silvia Pastorekova, Ala Yaromina, Claudiu T. Supuran, Ludwig J. Dubois, Jean-Yves Winum, Philippe Lambin http://dx.doi.org/10.1016/j.ejmech.2016.10.037
2016
2015
Keulers TG, Schaaf MB, Peeters HJ, Savelkouls KG, Vooijs M, Bussink J, Jutten B, Rouschop KM. GABARAPL1 is required for increased EGFR membrane expression during hypoxia. Radiother Oncol. 2015 Jul 8. pii: S0167-8140(15)00316-3. doi: 10.1016/j.radonc.2015.06.023. [Epub ahead of print] PubMed PMID: 26164772. 2:
Yahyanejad S, van Hoof SJ, Theys J, Barbeau LM, Granton PV, Paesmans K, Verhaegen F, Vooijs M. An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. Radiother Oncol. 2015 Jul 7. pii: S0167-8140(15)00313-8. doi: 10.1016/j.radonc.2015.06.020. [Epub ahead of print] PubMed PMID: 26163089.
Dubois L, Biemans R, Reniers B, Bosmans G, Trani D, Podesta M, Kollaard R, Rouschop KM, Theys J, Vooijs M, Pruschy M, Verhaegen F, Lambin P. High dose rate and flattening filter free irradiation can be safely implemented in clinical practice. Int J Radiat Biol. 2015 Aug 27:1-8. [Epub ahead of print] PubMed PMID: 26136086.
Xu X, Choi SH, Hu T, Tiyanont K, Habets R, Groot AJ, Vooijs M, Aster JC, Chopra R, Fryer C, Blacklow SC. Insights into Autoregulation of Notch3 from Structural and Functional Studies of Its Negative Regulatory Region. Structure. 2015 Jul 7;23(7):1227-35. doi: 10.1016/j.str.2015.05.001. Epub 2015 Jun 4. PubMed PMID: 26051713; PubMed Central PMCID: PMC4497832.
Granton PV, Yahyanejad S, Vooijs MA. SmART-ER imaging and treatment of glioblastoma. J Neurooncol. 2015 Jun;123(2):319-20. doi: 10.1007/s11060-015-1801-6. Epub 2015 May 8. PubMed PMID: 25952254.
Habets RA, Groot AJ, Yahyanejad S, Tiyanont K, Blacklow SC, Vooijs M. Human NOTCH2 Is Resistant to
Ligand-independent Activation by Metalloprotease Adam17. J Biol Chem. 2015 Jun 5;290(23):14705-16. doi: 10.1074/jbc.M115.643676. Epub 2015 Apr 27. PubMed PMID: 25918160; PubMed Central PMCID: PMC4505536.
Schaaf MB, Jutten B, Keulers TG, Savelkouls KG, Peeters HJ, van den Beucken T, van Schooten FJ, Godschalk RW, Vooijs M, Rouschop KM. Canonical autophagy does not contribute to cellular radioresistance. Radiother Oncol. 2015 Mar;114(3):406-12. doi: 10.1016/j.radonc.2015.02.019. Epub 2015 Mar 13. PubMed PMID: 25779723.
K, Imai T, Kressler C, Yagita H, Agata Y, Vooijs M, Hamazaki Y, Inoue J, Minato N.Crucial role of the Rap G protein signal in Notch activation and leukemogenicity of T-cell acute lymphoblastic leukemia.
Sci Rep. 2015 Jan 23;5:7978. doi: 10.1038/srep07978.
Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, Dubois L, Lambin P. A Comparative Study of the Hypoxia PET Tracers [(18)F]HX4, [(18)F]FAZA, and [(18)F]FMISO in a Preclinical Tumor Model. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):351-9.
Trani D, Reniers B, Persoon L, Podesta M, Nalbantov G, Leijenaar RTH, Granzier M, Yaromina A, Dubois L, Verhaegen F, Lambin P. What level of accuracy is achievable for preclinical dose painting studies on a clinical irradiation platform? Rad Res 2015
Peeters SG, Dubois L, Lieuwes NG, Laan D, Mooijer M, Schuit RC, Vullo D, Supuran CT, Eriksson J, Windhorst AD, Lambin P. [18F]VM4-037 microPET imaging and biodistribution of two in vivo CAIX-expressing tumor models. Mol Imaging Biol 2015
van Gisbergen MW, Voets AM, Starmans MHW, de Coo IFM, Yadak R, Hoffmann RF, Boutros PC, Smeets HJM, Dubois L, Lambin P. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutation Research 2015
2015
2014
2014
Zegers CM, Rekers NH, Quaden DH, Lieuwes NG, Yaromina A, Germeraad WT, Wieten L, Biessen EA, Boon L, Neri D, Troost EG, Dubois LJ, Lambin P. Radiotherapy combined with the immunocytokine (L19-IL2) provides long-lasting anti-tumor effects. Clin Cancer Res. 2014 Dec 31. pii: clincanres.2676.2014. [Epub ahead of print]
Peeters SG, Zegers CM, Yaromina A, van Elmpt W, Dubois L, Lambin P. Current pre-clinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging. 2014 Dec 17. [Epub ahead of print]
Marsch E, Theelen TL, Demandt JA, Jeurissen M, van Gink M, Verjans R, Janssen A, Cleutjens JP, Meex SJ, Donners MM, Haenen GR, Schalkwijk CG, Dubois LJ, Lambin P, Mallat Z, Gijbels MJ, Heemskerk JW, Fisher EA, Biessen EA, Janssen BJ, Daemen MJ, Sluimer JC. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2545-53
Granton PV#, Dubois L#, van Elmpt W, van Hoof SJ, Lieuwes NG, De Ruysscher D, Verhaegen F. A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):696-704.
Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2014 Oct 27:1-33.
Yahyanejad S#, Granton PV#, Lieuwes NG, Gilmour L, Dubois L, Theys J, Chalmers A, Verhaegen F, Vooijs M. Small animal imaging platform for orthotopic brain tumors. Mol Imaging Biol 2014 Oct 23;13:1-8.
Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother. 2014 Oct;18(5-6):391-5.
Caolo V, Swennen G, Chalaris A, Wagenaar A, Verbruggen S, Rose-John S, Molin DG, Vooijs M, Post MJ. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis. Angiogenesis. 2014 Sep 14. [Epub ahead of print]
Arjan J. Groot, Roger Habets, Sanaz Yahyanejad, Caroline M. Hodin, Karina Reiss,Paul Saftig, Jan Theys and Marc Vooijs. Regulated proteolysis of NOTCH2 and NOTCH3 receptors by A-Disintegrin-And-Metalloproteinase (ADAM) 10 and Presenilins. Mol. Cell. Biol. published ahead of print 19 May 014 , doi:10.1128/MCB.00206-14
Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG, Starmans MH, Boutros PC, Vooijs M, van Engeland M, Lambin P. Epigenetics in radiotherapy: where are we heading? Radiother Oncol. 2014 May;111(2):168-77
Rampanelli E, Rouschop KM, Claessen N, Teske GJ, Pals ST, Leemans JC, Florquin S. Opposite role of CD44-standard and CD44-variant-3 in tubular injury and development of renal fibrosis during chronic obstructive nephropathy.Kidney Int. 2014 Apr 9. doi: 10.1038/ki.2014.87. [Epub ahead of print]
Jutten B, Rouschop KM. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance.Cell Cycle. 2014 Jan 1;13(1):42-51
Heap JT, Theys J, Ehsaan M, Kubiak AM, Dubois L, Paesmans K, Mellaert LV, Knox R, Kuehne SA, Lambin P, Minton NP. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget. 2014 Apr 15;5(7):1761-9
Hoeben BA, Starmans MH, Leijenaar RT, Dubois LJ, van der Kogel AJ, Kaanders JH, Boutros PC, Lambin P, Bussink J. Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer. 2014 Feb 26;14:130. doi: 10.1186/1471-2407-14-130
Akurathi V, Dubois L, Celen S, Lieuwes NG, Chitneni SK, Cleynhens BJ, Innocenti A, Supuran CT, Verbruggen AM, Lambin P, Bormans GM. Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. Eur J Med Chem. 2014 Jan;71:374-84
Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, Pruschy M, Baumann M, Yaromina A, Zips D. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):159-66
2013
2013
Mujcic H, Nagelkerke A, Rouschop KM, Chung S, Chaudary N, Span PN, Clarke B, Milosevic M, Sykes J, Hill RP, Koritzinsky M, Wouters B: Hypoxic Activation of the PERK/eIF2α arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3. Clin Cancer Res. 2013 Nov 15;19(22):6126-37
Nichols AC, Chan-Seng-Yue M, Yoo J, Agrawal SK, Starmans MHW, Waggott D, Harding NJ, Dowthwaite SA, Palma DA, Fung K, Wehrli B, Macneil SD, Lambin P, Winquist E, Koropatnick J, Mymryk JS, Boutros PC, Barrett JW: A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases. Case Rep Oncol Med. 2013;2013:270362
John T, Starmans MHW, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS: The role of cancer-testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One. 2013 Jul 23; 8(7):e67876
De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, Hoebers F, Vooijs M, Ollers M, Lambin P: State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer. 2013 Mar;14(2):89-95
Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, Biemans R, Rami M, Parvathaneni NK, Vullo D, Vooijs M, Supuran CT, Winum JY, Lambin P: Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiother Oncol. 2013, doi:pii: S0167-8140(13)00297-
El Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P, De Windt LJ: The Hypoxia-Inducible MicroRNA Cluster miR-199a∼214 Targets Myocardial PPARδ and Impairs Mitochondrial Fatty Acid Oxidation. Cell Metab. 2013, 18(3):341-54
Theys J, Yahyanejad S, Habets R, Span P, Dubois L, Paesmans K, Kattenbeld B, Cleutjens J, Groot AJ, Schuurbiers OC, Lambin P, Bussink J, Vooijs M: High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol. 2013 Jul 25. doi:pii: S0167-8140(13)00299-5
Rampanelli E, Rouschop KM, Teske GJ, Claessen N, Leemans JC, Florquin S: CD44v3-v10 reduces the pro-fibrotic effects of TGF-β1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy. Am J Physiol Renal Physiol. 2013;305(10):F1445-54
Jutten B, Keulers TG, Schaaf MB, Savelkouls KG, Theys J, Span PN, Vooijs MA, Bussink J, Rouschop KM: EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiother Oncol. 2013, 108(3):479-83
Nabatov AA, Hatzis P, Rouschop KM, van Diest P, Vooijs M. Hypoxia inducible NOD2 interacts with 3-O-sulfogalactoceramide and regulates vesicular homeostasis. Biochim Biophys Acta. 2013, 1830(11):5277-86
Schaaf MB, Cojocari D, Keulers TG, Jutten B, Starmans MHW, Jong MD, Begg A, Savelkouls KG, Bussink J, Vooijs M, Wouters BG, Rouschop KM: The autophagy associated gene, ULK1, promotes tolerance to chronic and acute hypoxia. Radiother Oncol. 2013 Sep;108(3):529-34
Rouschop KM, Dubois L, van den Beucken T, Keulers T, Lambin P, Bussink J, van der Kogel AJ, Koritzinsky M and Wouters BG. PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. PNAS. 2013 March 110(12): 4622-4627
Lambin P, van Stiphout RGPM, Starmans MHW, Velazquez ER, Nalbantov G, Aerts HJWL, Roelofs E, van Elmpt W, Boutros PC, Granone P, Valentini V, Begg AC, De Ruysscher D, Dekker A: Prediction of outcome in radiation oncology: towards multifactorial decision support systems. Nat Rev Clin Oncol, 2013: 10(1): 27-40
Krause M, Kummer B, Deparade A, Eicheler W, Pfitzmann D, Yaromina A, Kunz-Schughart LA, Baumann M. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Radiother Oncol. 2013, 108:422-8
Koch U, Höhne K, von Neubeck C, Thames HD, Yaromina A, Dahm-Daphi J, Baumann M, Krause M. Residual γH2AX foci predict local tumour control after radiotherapy. Radiother Oncol. 2013, 108:434-9
Helbig H, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, Pruschy M, Baumann M, Yaromina A*, Zips D* (* equal contribution ). HIF pathway inhibition resolves tumor hypoxia and improves local tumor control after single dose irradiation. Int J Radiat Oncol Biol Phys 2013 (in press)
Liew MS, Sia J, Starmans MHW, Tafreshi A, Harris S, Feigen M, White S, Zimet A, Lambin P, Boutros PC, Mitchell P, John T: Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med. 2013 Dec;2(6):916-24
Ivanova I, Vermeulen J , Ercan C , Houthuijzen J , Al Saig F, Vlug E, van der Wall E, van Diest P, Vooijs M*, Dersken P* (equal contribution). FER kinase promotes breast cancer metastasis by regulating α6 and β1integrin-dependent cell adhesion and anoikis resistance. Oncogene 2013 Dec 12;32(50):5582-92
Groot AJ, Cobzaru C, Weber S, Saftig P, Blobel CP, Kopan R, Vooijs M*, Franzke CW*. (*equal contribution), Epidermal ADAM17 Is Dispensable for Notch Activation. J Invest Dermatol. 2013 Apr 3. doi: 10.1038/jid.2013.162. [Epub ahead of print]
Sarkar S, Germeraad WTV, Rouschop KM, Steeghs EMP, van Gelder M, Bos GJM, Wieten L. In situ hypoxia in Multiple Myeloma: An inhibitory factor for NK cell anti-myeloma response? PLoS One. 2013 May 28;8(5):e64835
Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, Lambin P, De Simone G, Supuran CT, Winum JY. Hypoxia-Targeting Carbonic Anhydrase IX Inhibitors by a New Series of Nitroimidazole-Sulfonamides/Sulfamides/Sulfamates. J Med Chem. 2013 Nov 14;56(21):8512-20
2012
2012
Groot AJ, Vooijs MA. The role of Adams in Notch signaling. Advances in experimental medicine and biology 2012, 727:15-36
Nagelkerke A, Mujcic H, Wouters B, Span PN. 18S is an appropriate housekeeping gene for in vitro hypoxia experiments. British journal of cancer 2012, 103(4):590; author reply 591-592
Quero L, Dubois L, Lieuwes NG, Hennequin C, Lambin P. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol. 2011 Oct;101(1):203-8
Wennemers M, Bussink J, Scheijen B, Nagtegaal ID, van Laarhoven HW, Raleigh JA, Varia MA, Heuvel JJ, Rouschop KM, Sweep FC et al. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Res. 2011 Aug 24;13(4):R82
Starmans MH, Lieuwes NG, Span PN, Haider S, Dubois L, Nguyen F, van Laarhoven HW, Sweep FC, Wouters BG, Boutros PC et al. Independent and functional validation of a multi-tumour-type proliferation signature. British journal of cancer 2012, 107(3):508-515
Starmans MH, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, Boutros PC, Wouters BG et al. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012, 102(3):436-443
2011
2011
MHW Starmans, G Fung, H Steck, BG Wouters, P Lambin. 'A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures'. Revisions 2011 PlosOne; 2011;6(12):e28320. Epub 2011 Dec 7
Wennemers M, Bussink J, Scheijen B, Nagtegaal ID, vanLaarhoven HWM, Raleigh JA, Varia MA, Heuvel JJTM, Rouschop KM, Sweep FCGJ, Span PN. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research. 2011 Aug 24;13(4):R82
Chantal Ramaekers, Brad Wouters. Regulatory functions of ubiquitin in diverse DNA damage responses. Current Molecular Medicine 2011 Mar;11(2):152-69. Review
Ercan C, van Diest PJ, Vooijs M. Mammary development and breast cancer: the role of stem cells. Curr Mol Med. 2011 Jun;11(4):270-85. Review
Tetering v G, Vooijs M. Proteolytic cleavage of notch: “hit and run”. Current Molecular Medicine 2011;11:270-85Current Molecular Medicine 2011;11:255-69
Seeber LM, Horrée N, Vooijs MA, Heintz AP, van der Wall E, Verheijen RH, van Diest PJ. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol. 2011 Jun;78(3):173-84
Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S, Carta F, McIntyre A, Scozzafava A, Dogné JM, Supuran CT, Harris AL, Masereel B, Lambin P. Radiother Oncol. 2011 Jun;99(3):424-31. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiotherapy and Oncology 99 (2011) 424–431
Quero L, Dubois L, Lieuwes NG, Hennequin C, Lambin P. miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer. Radiother Oncol 2011 Oct;101(1):203-8
Rouschop KM, Dubois L, Schaaf MB, van den Beucken T, Lieuwes N, Keulers TG, Savelkouls KG, Bussink J, van der Kogel AJ, Koritzinsky M, Wouters BG. Deregulation of cap-dependent mRNA translation increases tumour radiosensitivity through reduction of the hypoxic fraction. Radiother Oncol. 2011 Jun;99(3):385-91
Dubois L, Lieuwes NG, Janssen MHM, Peeters WJM, Windhorst AD, Walsh JC, Kolb HC, Öllers MC, Bussink J, van Dongen GAMS, van der Kogel A, Lambin P. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14620-5
Grootjans J, Hodin CM, de Haan JJ, Derikx JP, Rouschop KM, Verheyen FK, van Dam RM, Dejong CH. Level of activation of the unfolded protein response correlates with Paneth cell apoptosis in human small intestine exposed to ischemia/reperfursion. Gastroenterology, 2011 Feb;140(2):529-539e3
2010
2010
Ramaekers CH, van den Beucken T, Meng A, Kassam S, Thoms J, Bristow RG, Wouters BG. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol 2011, 101(1): 190-197
Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, Wouters BG. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010 Jan;120(1):127-41. doi: 10.1172/JCI40027. Epub 2009 Dec 14
Mellor HR, Rouschop KM, Wigfield SM, Wouters BG, Harris AL. Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. Biochem Pharmacol. 2010 Jan 25. [Epub ahead of print]
Hughes JM, Groot AJ, van der Groep P, Sersansie R, Vooijs M, van Diest PJ, Van Noorden CJ, Schlingemann RO, Klaassen I. Active HIF-1 in the normal human retina. J Histochem Cytochem. 2010 Mar;58(3):247-54. Epub 2009 Nov 9
Van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, Dingemans AM, Lalisang R, Brans B, Windhorst B, van Dongen GA, Kolb H, Zhang J, De Ruysscher D, Lambin P. PET imaging of hypoxia using [(18)F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010, 37(9):1663-8
Van de Sluis B, Mao X, Zhai Y, Groot AJ, Vermeulen JF, van der Wall E, van Diest PJ, Hofker MH, Wijmenga C, Klomp LW, Cho KR, Fearon ER, Vooijs M, Burstein E. COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest. 2010 Jun 1;120(6):2119-30
Schults MA, Timmermans L, Godschalk RW, Theys J, Wouters BG, van Schooten FJ, Chiu RK. Diminished carcinogen detoxification is a novel mechanism for hypoxia inducible factor 1 (HIF-1) mediated genetic instability. J Biol Chem. 2010 285(19):14558-64
Akurathi V, Dubois L, Lieuwes NG, Chitneni SK, Cleynhens BJ, Vullo D, Supuran CT, Verbruggen AM, Lambin P, Bormans GM. Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of Carbonic. Anhydrase IX (CA IX) expression in tumor hypoxia. Nucl Med Biol. 2010 Jul;37(5):557-64
Rami M, Montero JL, Dubois L, Lambin P, Scozzafava A, Winum JY, Supuran CT. Carbonic anhydrase inhibitors: Gd(III) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII.New J. Chem., 2010, 34, 2139–2144
Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, Starmans MH, van Stiphout RG, van Dongen GA, Muylle K, Flamen P, Dekker AL, De Ruysscher D. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol. 2010 Aug;96(2):145-52
Boutros PC, Pintillie M, John T, Starmans MHW, Der SD, Shepherd FA, Tsao MS, Jurisaca I. Re: Gene Expression-based Prognostic Signatures in Lung Cancer: Ready for Clinical Use? J Natl Cancer Inst. 2010 102(21):1677
Suijkerbuijk KP, Pan X, van der Wall E, van Diest PJ, Vooijs M. Comparison of different promoter methylation assays in breast cancer. Anal Cell Pathol (Amst). 2010;33(3):133-41
